J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J.
Right arrow Articles by Bertino JS
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J.
Right arrow Articles by Bertino JS, , Jr
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques

JS Kim, AN Nafziger, SM Tsunoda, EE Choo, DS Streetman, AD Kashuba, RW Kulawy, DJ Beck, Rocci ML Jr, GR Wilkinson, DJ Greenblatt, and Bertino JS Jr

Midazolam clearance is used to phenotype hepatic CYP3A activity but requires multiple plasma samples following a single intravenous dose. The authors evaluated the use of a limited sampling scheme, using different assay techniques to determine the reproducibility of such a strategy in estimating midazolam AUC. Seventy-three healthy adults received midazolam as a single intravenous bolus dose. At least eight plasma samples were collected from each subject and were assayed using either LC/MS/MS or electron capture gas chromatography. Eleven subjects were randomly selected for the training set using stepwise linear regression to determine relationships between midazolam plasma concentrations and AUC. Validation of the predictive equations was done using the remaining 62 subjects. Mean percent error (MPE), mean absolute error (MAE), and root mean square error (RMSE) were calculated to determine bias and precision. Based on the training set, five models were generated with coefficients of determination ranging from 0.87 to 0.95. Validation showed that MPE, MAE, and RMSE values were acceptable for three of the models. Intrasubject reproducibility was good. In addition, training set datafrom one institution were able to predict data from the other two institutions using other assay techniques. Minimized plasma sampling mayprovide a simpler method for estimating midazolam AUC for CYP3A phenotyping. A limited sampling strategy is more convenient and cost-effective than standard sampling strategies and is applicable to more than one assay technique.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Lab AnimHome page
X.-H. Zhu, J.-J. Jiao, C.-L. Zhang, J.-S. Lou, and C.-X. Liu
Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A
Lab Anim, July 1, 2009; 43(3): 284 - 290.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. R. Penzak, K. H. Busse, S. M. Robertson, E. Formentini, R. M. Alfaro, and R. T. Davey Jr.
Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A-Mediated Drug Interactions
J. Clin. Pharmacol., June 1, 2008; 48(6): 671 - 680.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
L. S. Lee, J. S. Bertino Jr, and A. N. Nafziger
Limited Sampling Models for Oral Midazolam: Midazolam Plasma Concentrations, Not the Ratio of 1-Hydroxymidazolam to Midazolam Plasma Concentrations, Accurately Predicts AUC as a Biomarker of CYP3A Activity
J. Clin. Pharmacol., February 1, 2006; 46(2): 229 - 234.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Lepper, S. D. Baker, M. Permenter, N. Ries, R. H.N. van Schaik, P. W. Schenk, D. K. Price, D. Ahn, N. F. Smith, G. Cusatis, et al.
Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients
Clin. Cancer Res., October 15, 2005; 11(20): 7398 - 7404.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. H. J. Mathijssen, F. A. de Jong, R. H. N. van Schaik, E. R. Lepper, L. E. Friberg, T. Rietveld, P. de Bruijn, W. J. Graveland, W. D. Figg, J. Verweij, et al.
Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
J Natl Cancer Inst, November 3, 2004; 96(21): 1585 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. D. Ma, A. N. Nafziger, A. D. M. Kashuba, M.-J. Kim, A. Gaedigk, E. Rowland, J. S. Kim, and J. S. Bertino Jr.
Limited Sampling Strategy of S-Warfarin Concentrations, but Not Warfarin S/R Ratios, Accurately Predicts S-Warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers
J. Clin. Pharmacol., June 1, 2004; 44(6): 570 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Panetta, L. C. Iacono, P. C. Adamson, and C. F. Stewart
The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development
Clin. Cancer Res., November 1, 2003; 9(14): 5068 - 5077.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Clinical Pharmacology